Jonathan Rachman, M.D., Ph.D.
Senior Vice President and Head of Diabetes/Obesity R&D

Dr. Jonathan Rachman is currently Senior Vice President and Head of Diabetes/Obesity Research & Development. He joined OSI as Vice President Clinical Development in April 2005. Dr. Rachman started his medical career in Cape Town, South Africa where he complemented his MB ChB with a BSc Hons in Medical Biochemistry. Having acquired Membership of the Royal College of Physicians, he built on an early interest in endocrinology, spending four years in Oxford, UK completing a DPhil at the University of Oxford's Diabetes Research Laboratories. His research focused on the effects of existing and novel therapeutic agents on beta-cell function in type 2 diabetes, and he conducted several studies on the effects of GLP-1.

Dr. Rachman’s commercial career, now approaching thirteen years, began with Pfizer in the UK. He started as Clinical Project Manager in the European Experimental Medicine R&D facility, and following leadership of projects in several therapeutic areas, he progressed to Director, Early Therapeutic Area Leader within tissue repair. He joined Eli Lilly & Co. in July 2001 as Clinical Research Physician and Medical Advisor in diabetes. He was promoted to Lead Clinical Research Physician for endocrinology and diabetes within the UK, contributing to clinical programmes and leading interactions with the UK's Medical Devices Agency. Dr. Rachman contributed to the diabetes-focused GLP-1 programme and the European Phase III study designs for Exenatide®, Amylin's GLP-1 analogue which was jointly developed with Lilly. He has acquired the UK Diploma in Pharmaceutical Medicine and is a member of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians.

From November 2006, Dr. Rachman led the OSI Diabetes/Obesity Development function, responsible for all aspects of CMC, Pre-Clinical Safety, DMPK, and Clinical Research and Operations, and in September 2009, he assumed leadership of Diabetes/Obesity Research & Development.